Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

What is next, and who is running it?

The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Include Phase 1
ClassNone selected

21 of 23 programs on this timeline

202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today

AstraZeneca 1

Registry, Dec 31, 2029

Ayala Pharmaceuticals 1

No dated milestone in 2025 to 2030

Cellestia Biotech 1

CB-103Phase 1/2
Registry, Jun 2027

Dana-Farber Cancer Institute 1

Registry, Jul 2027

Eisai (investigator studies) 1

Registry, Dec 2026

Elevar Therapeutics 1

RivoceranibTrials stopped
No dated milestone in 2025 to 2030

Exelixis 1

Registry, Apr 2029

Eye and ENT Hospital of Fudan University 1

Registry, Jun 2028

HitGen 1

HG146Phase 2
Registry, Dec 31, 2028

Memorial Sloan Kettering 1

Registry, Mar 2027

Memorial Sloan Kettering (investigator) 1

No dated milestone in 2025 to 2030

National Cancer Centre Singapore 1

Registry, Oct 31, 2028

National Cancer Institute 1

Registry, Oct 2036

Pfizer 1

No dated milestone in 2025 to 2030

Radboud UMC; Johns Hopkins (investigators) 1

No dated milestone in 2025 to 2030

Remix Therapeutics (merging with Passage Bio) 1

REM-422Phase 1/2
ENA 2026 late-breaking oral 5LBA (updated Phase 1), Nov 19, 2026Initial Phase 2 data (company guidance), H1 2027Registry, Sep 30, 2027

Servier (registry sponsor Day One Biopharmaceuticals) 1

EMBLEM-1 first patients dosed, Oct 19, 2026Registry, Feb 2027

Shanghai Ninth People's Hospital 1

ApatinibPhase 2
No dated milestone in 2025 to 2030

Trisha Wise-Draper (investigator) 1

No dated milestone in 2025 to 2030

University of Michigan 1

No dated milestone in 2025 to 2030

VM Oncology 1

VMD-928Phase 1/2
Registry, Dec 2027